Nephrogen participated in this spring's session of the accelerator program at StartX. We learned a lot during the session and are excited to bring our knowledge and connection with the StartX as we raise our seed round.
Nephrogen is happy to announce that we have officially moved our corporate headquarters to Palo Alto, California! All corporate and R&D work will be performed at our new headquarters, and we are very excited to take advantage of the amazing opportunities available to us in Silicon Valley.
Today Nephrogen announced the official opening of a new R&D facility in Bethel, ME. This laboratory is equipped with a mammalian cell culture facility certified to handled BSL-2 agents, sufficient incubator and cold storage space, a separate area for running molecular biology assays, and a small office. This laboratory will serve as the primary headquarters for Nephrogen's R&D work for the next year, but the corporate headquarters will remain in Lexington, MA.
Nephrogen's first patent application was published online today with CEO Demetri Maxim as the sole inventor. It details a device currently in the pipeline that provides a simple, rapid, inexpensive, and minimally invasive method for detecting blood biomarkers of various life threatening diseases. This technology and underlying IP is currently being applied by Nephrogen to provide novel medical devices that aid in the early detection of chronic kidney transplant rejection. Check out the full patent here.
Today, Team Nephrogen participated in the Boston Walk for PKD, which is a one of the largest fundraisers for the PKD Foundation. The PKD Foundation is a non-profit organization dedicated to funding research to lead the fight against PKD, and our team raised a total of $1000 to put towards this great cause! Here is a picture of CEO Demetri Maxim at the end of the walk.
Demetri also had lunch with PKD Foundation CEO Jackie Hancock and Chief Development Officer, Michelle Davis, after the walk to discuss future funding and development opportunities.